STOCK TITAN

BIOTRICITY INC - BTCY STOCK NEWS

Welcome to our dedicated page for BIOTRICITY news (Ticker: BTCY), a resource for investors and traders seeking the latest updates and insights on BIOTRICITY stock.

Biotricity, Inc. (BTCY) is a medical technology company at the forefront of healthcare innovation. Specializing in biometric data monitoring solutions, Biotricity aims to improve healthcare by developing remote monitoring solutions for chronic disease prevention and management. Its premier product, Bioflux, is an ECG monitoring system used by physicians to diagnose and monitor cardiac patients remotely. Biotricity's Biolife solution extends medical-grade monitoring to the consumer market, empowering users to self-manage chronic conditions through lifestyle changes. With a focus on preventive healthcare, Biotricity's R&D efforts aim to put health management directly into the hands of individuals, easing the burden on the healthcare system.

Rhea-AI Summary

Biotricity, Inc. (Nasdaq:BTCY) has reported significant operational achievements since FY22, showcasing its robust growth and innovation in the healthcare market. Key highlights include:

  • Recognition by TIME magazine as one of the Best Inventions of 2022 for its Bioheart heart monitor.
  • Ranked No. 1 among the Top 10 Most Innovative Medical Device Companies by Fast Company.
  • Launch of the Biocare™ Cardiac Disease Management Solution, aiding over 2,000 cardiologists.
  • Winning an NIH grant for AI-driven monitoring solutions.
  • Expansion to 300+ centers across 30 states.

The healthcare biometric market is projected to grow from $26.9 billion in 2021 to $78.4 billion by 2030.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.69%
Tags
none
-
Rhea-AI Summary

Biotricity Inc. (Nasdaq:BTCY) reported strong financial results for the third quarter of fiscal 2023, ending December 31, 2022. Revenue grew 27.4% year-over-year to $2.46 million, achieving a gross margin of 57%. The company successfully signed two significant distribution agreements, contributing to its strategic market growth. Notably, Biotricity maintained a 98% customer retention rate, bolstering its subscription revenue model. The net loss was reduced by a third, totaling $4.75 million. As Biotricity focuses on achieving positive cash flow, it plans to optimize its R&D and capex investments while continuing product innovation.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.27%
Tags
-
Rhea-AI Summary

Biotricity Inc. (NASDAQ:BTCY) will host a conference call on February 14, 2023, at 4:30 p.m. ET to discuss its third-quarter financial results for fiscal 2023. The call will cover important financial metrics and provide insights on the company's performance. Interested participants can join via a toll-free number or through a live webcast. A replay of the call will be accessible until February 28, 2023. Biotricity focuses on enhancing remote health monitoring and chronic care management, aiming to bridge gaps in healthcare delivery.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.02%
Tags
conferences earnings
Rhea-AI Summary

Biotricity (NASDAQ:BTCY) has been selected to present at the 2nd Annual Innovation Showcase during the American Stroke Association 2023 International Stroke Conference in Dallas, TX on February 9. This prestigious event features only eight companies, emphasizing Biotricity's innovation in medical technology. The Company will showcase its research on stroke prediction in patients with chronic kidney disease (CKD), supported by a recent NIH grant. This research aims to improve monitoring and therapeutic strategies for high-risk CKD patients, potentially reducing mortality rates and healthcare costs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
conferences
-
Rhea-AI Summary

Biotricity Inc. (NASDAQ:BTCY) has announced a second distribution agreement with a leading US medical device distributor for its cardiac monitoring solutions, Bioflux and Biotres. Designed for cardiologists, these solutions will be marketed directly to hospitals and clinics. Founder and CEO Waqaas Al-Siddiq emphasized the significance of advanced technology in enhancing remote patient care. He pointed out that Biotricity aims to capture a share of the $6 billion cardiac care market, delivering 24/7 remote monitoring capabilities that could improve heart disease outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.5%
Tags
none
-
Rhea-AI Summary

Biotricity (NASDAQ:BTCY) has announced that CEO Waqaas Alsiddiq will speak at the upcoming Healthcare IT Virtual Conference on January 25, 2023, at 8:15 a.m. ET. This conference, hosted by Maxim Group LLC and M-Vest, addresses technological advancements in healthcare aimed at reducing costs and improving patient outcomes. Participants will explore various companies including Biotricity, focusing on remote monitoring and chronic care management. Attendees can join live by signing up as M-Vest members. For more information and to reserve a seat, visit the provided link.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.83%
Tags
conferences
Rhea-AI Summary

Biotricity Inc. (NASDAQ:BTCY) announced a partnership with a leading group purchasing organization (GPO) to distribute its cardiac monitoring solutions, Bioflux and Biotres. This collaboration targets hundreds of independent US hospitals and clinics, facilitating bulk purchasing of medical devices. According to CEO Waqaas Al-Siddiq, this agreement is expected to enhance the company’s visibility and drive revenue growth throughout 2023. Biotricity focuses on remote monitoring and chronic care management, aiming to improve cardiology services and patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.02%
Tags
none
-
Rhea-AI Summary

Biotricity, Inc. (Nasdaq: BTCY) announced a 510(k) submission to the FDA for a new form factor of its Biotres Cardiac Monitoring Device. This device targets the $5 billion holter monitor market, focusing on lower-risk patients. Key features include 3-channel ECG recording, a rechargeable battery lasting 48 hours, wireless connectivity for faster diagnoses, a user-friendly design, and a modular approach for future enhancements. The company aims to improve patient lives and reduce healthcare costs through innovative technology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.83%
Tags
none
-
Rhea-AI Summary

Biotricity Inc. (NASDAQ:BTCY) has signed a distribution agreement with a Top 10 US medical distributor to expand the commercialization of its cardiac monitoring solutions, targeting a market of $6 billion. The company has a 95% customer retention rate and significant achievements, including a $250K NIH grant for AI-driven monitoring. Upcoming plans include broadening distribution and developing new products to enhance revenue growth and reduce expenses, aiming for profitability by capitalizing on existing and new partnerships.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.36%
Tags
none
Rhea-AI Summary

Biotricity Inc. (NASDAQ:BTCY) has signed a distribution agreement with a leading US medical device distributor to enhance the availability of its cardiac monitoring solutions, Bioflux and Biotres. This partnership is expected to significantly expand Biotricity's market reach, increasing its total addressable market from $1 billion to approximately $6 billion. The company aims to solidify its position as a comprehensive solution for cardiac diagnostics while planning to provide further partnership details in the coming months.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.86%
Tags
none

FAQ

What is the current stock price of BIOTRICITY (BTCY)?

The current stock price of BIOTRICITY (BTCY) is $0.28 as of December 20, 2024.

What is the market cap of BIOTRICITY (BTCY)?

The market cap of BIOTRICITY (BTCY) is approximately 14.3M.

What is Biotricity, Inc.?

Biotricity, Inc. is a medical technology company focused on developing biometric data monitoring solutions for chronic disease prevention and management.

What are some of Biotricity's products?

Biotricity's premier product is Bioflux, an ECG monitoring system used for diagnosing and remotely monitoring cardiac patients. The company also offers Biolife, a consumer-focused solution for self-managing chronic conditions.

What is the vision of Biotricity, Inc.?

Biotricity aims to empower individuals by providing innovative solutions for preventive healthcare, ultimately enabling users to take control of their health and manage critical conditions effectively.

How does Biotricity contribute to the healthcare industry?

Biotricity's focus on remote monitoring and chronic care management bridges the gap in healthcare services, offering diagnostic and post-diagnostic solutions for chronic conditions, particularly in the cardiology sector.

BIOTRICITY INC

Nasdaq:BTCY

BTCY Rankings

BTCY Stock Data

14.29M
14.43M
40.89%
2.19%
2.07%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States of America
REDWOOD CITY